Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Pharmos (PARS) -- Ignore unavailable to you. Want to Upgrade?

To: Richard Huth who wrote (10)	10/30/1998 10:59:00 AM
From: yosi s	Read Replies (2) \| Respond to of 1386

What I gather from the nerve gas trial is neuroprotection. There is a group of patients that gets epilepsy. and some of those develop intractable seizures. That can cause sever brain damage. It is in this population that the study can be done. Also there are certain metabolic disorders that predispose for intractable seizures. Though patient population is small, a study design can show in a short time potential protection by HU 211 from the damaging effect of intractable seizures. Keep im mind that even in brain trauma those patients develop seizures. I would suggest to look at the data and to see if those patients that had seizures and if they form a sub group.